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1. Introduction 
Melanoma is a malignant tumor originating from melanocytes (pigment-producing cells). 
Although the tumor is mainly detected in skin (cutaneous melanoma), it can also be 
detected in the eye (uveal melanoma), gastrointestinal (GI) tract and oral mucosa and genital 
tract (mucosal melanoma) (Landreville et al., 2008; Akaraviputh et al., 2010; Bakalian et al., 
2008; Rigel et al., 2010; Seetharamu et al., 2010). Melanoma can be classified as belonging to 
one of four subtypes: superficial spreading, nodular, lentigo maligna, and acral lentiginous 
melanoma. These subtypes are characterized based on prognosis, incidence of metastasis 
and the frequency of gene mutations (e.g., BRAF and NRAS) (Saldanha et al., 2006; Jaeger et 
al., 2007; Markovic et al., 2007; Jönsson et al., 2010). Superficial spreading melanoma is the 
most common form of melanoma found in Caucasian populations, while the acral 
lentiginous melanoma is frequently detected in Asian and African populations (Cress and 
Holly, 1997; Weyers et al., 1999). 
Several important risk factors that have been linked to the development of melanoma have 
been identified. Of these risk factors, most can be considered to be either environmental 
factors, such as exposure to ultraviolet (UV) radiation, especially in childhood, or other 
host factors such as family history and melanocytic nevi (Markovic et al., 2007; Schulman 
and Fisher, 2009), but other cancer risk factors such as smoking (Osterlind et al., 1988), diet 
(Osterlind et al., 1988; Veierod et al., 1997) or hormone therapy (Naldi et al., 2005) have not 
been found to be associated with an increased risk of melanoma. The risk of developing 
melanoma is higher in Caucasian than in Asian or African populations. This is closely 
related to skin pigmentation as melanin has been shown to have a protective function for 
UV-induced melanoma and Caucasian populations show low levels of melanogenesis 
(Lens and Dawes, 2004; Hu et al., 2008; Jemal et al., 2010). In general, the melanocortin-1 
receptor (MC1R), which is a G-protein-coupled receptor (GPCR), stimulates melanogenesis 
through the activation of adenylate cyclase and protein kinase A (PKA) (Jordan and 
Jackson, 1998; Rouzaud et al., 2003). Its genetic variants are associated with melanoma 
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incidence and sun sensitivity (Box et al., 2001; Markovic et al., 2007). Moreover, the risk of 
developing melanoma is greater in males than in females over the age of 40, although the 
opposite effect is observed in patients under 40 years old (Lens and Dawes, 2004; Jemal et 
al., 2010). 
The global incidence of melanoma has increased over the past decades (Markovic et al., 
2007; Jemal et al., 2010, Rigel et al., 2010). The 5-year survival rate for melanoma is higher 
than for other prominent cancers such as tumors of the prostate, ovary, liver and bile duct, 
lung and bronchus, colon and rectum, and stomach. Yet, the early diagnosis and treatment 
of melanoma is crucial to increasing the survival rate (Jemal et al., 2010, Rigel et al., 2010). 
An important early diagnostic methodology for melanoma is the ABCDE criteria, which is 
defined by describing changes to the appearance of the suspected lesion based on the 
following features: Asymmetry, Border (irregularity), Color (variegation), Diameter and 
Evolution (over time). Other diagnostic strategies also typically utilized include histological 
and/or molecular analysis (e.g., genes or proteins profiling) of biopsied material, 
dermoscopy (also known as dermatoscopy or epiluminescent microscopy) using a light-
based magnification or digital (computer)-assisted device, ultrasound imaging and magnetic 
resonance imaging (Abbasi et al., 2004; Rigel et al., 2005; Markovic et al., 2007; Psaty and 
Halpern, 2009; Rigel et al., 2010). 
Recently there has also been a move toward establishing biomarkers for malignant 
melanoma. These types of biological markers are not only beneficial for the diagnosis of 
melanoma, but also allow physicians to monitor the recurrence of melanoma after surgical 
resection, or to monitor the effect of radiation or anticancer drug therapies. To identify 
putative melanoma biomarkers in tissue samples or body fluids, a number of methodologies 
can be utilized, including two-dimensional gel electrophoresis (2-DE) and high throughput 
microarray technology.  
2. Melanoma biomarkers 
2.1 Cellular signals and tissue biomarkers (immunohistochemical biomarkers) 
Signal transduction pathways are the mechanism through which cells respond to the 
extracellular signals (ligands) required to regulate or modulate downstream gene 
expression. These extracellular signals activate signal transduction pathways by either 
penetrating the cellular membrane or binding to specific receptors. The activated receptors 
are then able to change the quantity or intracellular distribution of the second messengers 
through the use of effector molecules. Second messengers also activate protein targets, 
which control downstream gene expression. In these cellular signal transduction pathways, 
phosphorylation of the target proteins (by protein kinases), or dephosphorylation or 
proteolytic cleavage (by proteases) play a key role in cell division and motility, apoptosis 
and carcinogenesis. 
In melanoma cells, major signal transduction pathways are RAS/RAF/MEK/ERK and the 
PI3K/AKT (as known as protein kinase B)/mTOR pathway; however, other pathways such 
as PLC/DAG/PKC or Wnt/β-catenin pathway have also been identified (Figure 1). The 
interaction of a number of different ligands [e.g., fibroblast growth factor (FGF), vascular 
endothelial growth factor (VEGF), or epidermal growth factor (EGF)] with their respective 
receptors [e.g., growth factor receptors (GFRs) (tyrosine kinase receptors)] leads to the 
stimulation of the RAS target protein, which has three members (HRAS, KRAS, and NRAS). 
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Phosphorylation of RAF kinase by RAS activates downstream targets the MAPK 
extracellular signal-regulated kinase-1 and -2 (MEK1 and MEK2), which causes the 
phosphorylation of extracellular signal-regulated kinase-1 and -2 (ERK1 and ERK2). 
Activated ERK1 and 2 has been found to modulate the gene expression necessary for 
survival and proliferation of melanoma cells, and has been linked to the increase resistance 
of melanoma cells to apoptosis by inhibiting the activation of caspase 8 (Becker et al., 2006; 
Sekulic et al., 2008). The BRAF mutation is necessary for ERK-mediated survival and 
proliferation and participates in the reduction of proapoptotic proteins (e.g., Bcl-2 family), 
while RAF genes consist of ARAF, BRAF, and CRAF (also known as Raf-1) (Becker et al., 
2006; Cartlidge et al., 2008; Sekulic et al., 2008). The BRAF mutation, predominantly V600E 
(substitution of glutamate to valine; previously known to V599E), frequently occurs in 
melanoma and is strongly related to exposure to UV radiation (Tsao et al., 2004; Wan et al., 
2004; Gray-Schopfer et al., 2005; Becker et al., 2006; Sekulic et al., 2008). 
 
 
Fig. 1. Intracellular signal transduction of melanoma. RAS/RAF/MEK/ERK, 
PI3K/AKT/mTOR, PLC/DAG/PKC, and Wnt/β-catenin pathways are associated with 
survival, proliferation angiogenesis, and apoptosis of melanoma cells. Melanoma cells show 
an increase in the expression of survival or proliferation-associated signals and 
angiogenesis-associated signals, but a decrease in the expression of tumor suppressor or 
apoptosis-associated signals 
www.intechopen.com
 Biomarkers Changes of expression 
Survival or proliferation-associated molecules 
GFRs (e.g., EGFR, VEGFR, FGFR, and PIGFR) 1) Increased  Lacal et al., 2000; 
Odorisio et al., 2
GPCRs (e.g., Wnt/fizzled receptor and  
chemokine receptors) 1) 
Increased  Lee et al., 2008 
c-kit, one of GPCRs Increased, but decreased  
in metastatic melanoma 
Janku et al., 2005 
Activated PI3K Increased Becker et al.,
Activated AKT Increased  Stahl et al., 2004 
Activated ERK1/2 Increased Cohen et al., 2002 
Activated protein kinase C (PKC)α Increased Lahn and Sundel
β-catenin 2) Increased Sanders et al., 19
Cytokines (e.g., IL-1, IL-6, IL-8, and IL-10) Increased Ciotti et al., 1995 
Heat shock proteins (HSPs) (e.g., HSP 27 or 90) Increased McCarthy et al.
Microphthalmia transcription factor (MITF) Increased, but decreased  
in metastatic melanoma 
Garraway et al., 
Fecker et al., 2006; Hoek et al., 2008 
Apoptosis-associated molecules 
Antiapoptotic Bcl-2 family (Bcl-2, Bcl-XL, and Mcl-1) Increased 3) Leiter et al., 2000
Proapoptotic Bcl-2 family (multidomain proteins;  
Bax and Bak) 
Decreased Fecker et al., 2006; Tch
Proapoptotic Bcl-2 family  
(BH3-only proteins; Bad, Bid, Bim, PUMA, and NOXA) 
Decreased Eisenmann
Ley et al., 2005; Qin
TRAIL-R1 (DR4) and TRAIL-R2 (DR5) Decreased Zhang et al., 1999; Zhua
Activated NF-κB Increased Ueda and Ric
Tumor suppressor-associated molecules 
p4ARF Decreased Krimpenfort
p16INK4A  Decreased Krimpenfort e
PTEN Decreased  Stahl et al., 2003; Wu et al., 2003 
Inhibitor of growth family member 3 (ING3) Decreased  Wang et al., 2007 
Angiogenesis-associated molecules 4) 
Chemokine receptors (CXCR1 and CXCR2);  
one family of GPCRs 
Increased Scala et al., 2005
Richmond et al., 
Matrix metalloproteinases (MMPs)  Increased Hofmann et al., 2
Urokinase plasminogen activator receptor (uPAR) Increased de Vries et al., 19
Metastasis-associated proteins 
Chemokine receptors (CXCR4, CCR7, and CCR10) 5) Increased Payne and 
Scala et al., 2005; Rich
Cell adhesion-associated molecules 
Cytoskeleton/structure proteins (e.g., vimentin) Increased Coupland et al., 
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 Biomarkers Changes of expression 
MUC18 Increased Lai et al., 2007 
Integrin αvβ3 Increased Hieken et al., 19
Integrin α6β4 Increased Nikolopoulos et 
N-cadherin Increased Li et al., 2001; Qi et al., 2005 
P-cadherin Decreased Sanders et al., 
E-cadherin 6) Decreased  Sanders et al., 19
Molina-Ortiz et al., 2009 
Antigens 7) 
Melanocyte lineage/differentiation antigens 
TRP1/gp75 Increased Thomson et al
Rad et al., 2004 
TRP2  Increased Winder et al., 19
Melan-A/MART-1 Increased Chen et al., 1998; Murer et al.,
Tyrosinase Increased Sonesson et al., 1
gp100/pmel-17 Increased Pardo et al., 2007
S100 proteins (e.g., S100B) Increased Henze et al., 1997; Sch
Melanoma inhibitory activity (MIA) Increased Bosserhoff et 
Schmidt and Bos
Cancer/testis antigens 
BAGE family Increased Simpson et al., 2
GAGE family  Increased Simpson et al., 2
MAGE family  Increased Simpson et al., 2
NY-ESO-1 Increased Chen et al., 1998; Simpso
Barrow et al., 2006 
Melanoma-associated antigens 
A 90-kDa glycoprotein  (e.g., TA-90 and periostin) Increased Rote et al., 1980; Kelley et al., 1998
Paulitschke e
Survivin (one of apoptosis inhibitors gene family) Increased Tas et al., 2004 
Other antigens 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) (a negative 
regulator for T cells) 
Increased O’Day et al., 2007; Robert an
Galectin-3 (a β-galactoside-binding protein) Increased Prieto et al., 2006
Preferentially expressed antigen of melanoma (PRAME) 
(a repressor of retinoic acid) 
Increased Epping and Bernards, 2006
Multiple myeloma1 (MUM1) (melanoma associated 
antigen) 
Increased Natkunam et al., 
Other tissue biomarkers 
Nodal/Cripto-1 (nodal coreceptor) Increased Topczewska et  
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Moreover, phosphorylation of AKT kinase by phosphatidyl inositol 3-kinase (PI3K) 
stimulates the mammalian target of rapamycin (mTOR), which leads to the survival and 
proliferation of melanoma cells. The AKT/mTOR pathway suppresses apoptosis by 
decreasing the levels of pro-apoptotic proteins (e.g., BAD and caspase-9). Among the three 
AKT members (AKT1, AKT2, and AKT3), it is AKT3 that is often overexpressed in 
melanoma (Stahl et al., 2004) and is regulated by the phosphatase and tensin homolog 
(PTEN), which degrades the products of PI3K (Wu et al., 2003; Becker et al., 2006; Sekulic et 
al., 2008).  
In addition, many antigens, which have immunostimulatory or activator roles in 
tumorigenesis, have been identified in metastatic melanoma. Important antigens include the 
melanocyte lineage/differentiation antigens [e.g., tyrosinase-related protein-1 (TRP1)/gp75, 
TRP2, Melan-A/MART-1] (Thomson et al., 1985; Winder et al., 1994; Murer et al., 2004; Rad 
et al., 2004) and cancer/testis antigens (e.g., BAGE family, GAGE family, MAGE family, and 
NY-ESO-1) (Chen et al., 1998; Simpson et al., 2005; Barrow et al., 2006). Melanocyte 
lineage/differentiation antigens are associated with the production of melanin pigments 
and have been identified in both normal melanocytes and melanoma (Thomson et al., 1985; 
Houghton et al., 1988). Cancer/testis antigens are abundant in normal tissues during 
development, but in mature cells, their expression is restricted to the male germ cells in the 
testis and to various tumors (Simpson et al., 2005).  
As indicated, several gene mutations such as NRAS (Q61K/R), BRAF (V600E), PTEN, and 
CDKN2A mutation play an important role in the occurrence of melanoma (Tsao et al., 2004; 
Wan et al., 2004; Gray-Schopfer et al., 2005; Becker et al., 2006; Sekulic et al., 2008). These 
mutations are excellent targets for the diagnosis of melanoma. Moreover, in the context of 
melanoma prognosis, melanoma cells show an increase in the expression of survival or 
proliferation-associated molecules, angiogenesis-associated molecules, and in the expression 
of antigens, but a decrease in the expression of tumor suppressor-associated proteins (e.g., 
PTEN) or proapoptotic proteins (e.g., Bax and Bak) is observed (Table 1). Thus, these 
molecules, which show altered expression levels in melanoma relative to normal cells, are 
useful tissue biomarkers (immunohistochemical biomarkers) for melanoma diagnosis. 
However, in spite of these discoveries, these markers are not specific to melanoma and there 
are few melanoma-specific tissue biomarkers, excluding melanocyte lineage/differentiation 
antigens and melanoma-associated antigens (e.g., TRP1/gp75 and 2, Melan-A/MART-1, 
and TA-90) that are overexpressed in metastatic melanoma. 
2.2 Serologic biomarkers for melanoma diagnosis 
Many researchers have identified putative serologic biomarkers for melanoma diagnosis 
(Table 2), which play a key role in the growth and survival of melanoma cells. Typically, 
these markers activate survival and/or proliferation-associated and angiogenesis-associated 
signal transduction pathways after binding with their receptors. The most important 
receptors of this kind are GFRs (e.g., VEGFR and FGFR) and GPCRs (e.g., MC1R, 
Wnt/frizzled receptor, and chemokine receptor) (Halaban, 1996; Lee et al., 2008).  
The primary antigens that have been observed in the serum of melanoma patients are 
melanocyte lineage/differentiation antigens and melanoma-associated antigens. The 
existence of these antigens in serum is closely associated with melanoma progression and 
low survival rates. Thus, these types of markers are useful as prognostic biomarkers and 
have potential to act as therapeutic targets. 
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In the absence of vascularization, the growth of melanoma is limited to 0.2 – 0.3 cm due to 
the limited diffusion of oxygen and nutrients into the tumor. For additional growth, 
angiogenesis is essential for providing adequate blood supply to the growing lesion. 
Angiogenesis is regulated by proangiogenic factors, such as VEGF, FGF, tumor necrosis 
factor (TNF), and interleukin-8 (IL-8) and by antiangiogenic factors, such as interferons 
(IFNs) and angiostatin. An increase in vascular density provides a greater supply of oxygen 
and nutrients to cells, leading to melanoma growth (Folkman, 2007; Mahabeleshwar and 
Byzova, 2007). High levels of proangiogenic factors in the serum of melanoma patients can 
be used as an indicator of melanoma at diagnosis. 
Multiple cytokines (e.g., IL-1, 4, 6, 8, 10 and 14), which are correlated with melanoma 
growth, angiogenesis and metastasis, have been observed in the serum of melanoma patient 
at both the protein and/or mRNA level. Serum levels of these cytokines are increased in 
metastatic melanoma patients, suggesting that they can be used as an indicator of melanoma 
progression (Porter et al., 2001; Varney et al., 2006; Yurkovetsky et al., 2007). Moreover, the 
serum concentration of the soluble IL-2 receptor is elevated in patients with metastatic 
melanoma and elevated serum IL-2 receptor levels are associated with lowered survival 
rates (Boyano et al., 1997; Ottaiano et al., 2006). Interestingly, IFNs are soluble cytokines, but 
possess antiangiogenic and antitumor activities. An increase in the melanoma progression-
associated cytokines leads to a reduction in IFNs levels, but there is a decrease in the serum 
levels of melanoma progression-associated cytokines in melanoma patients following 
immunomodulatory therapy with IFNs (mainly IFN-α2b)(Singh and Varner, 1998; Jonasch 
and Haluska, 2001; Yurkovetsky et al., 2007; Dummer and Mangana, 2009; Hofmann et al., 
2011). Thus, the analysis of a number of different serum cytokines may be a useful means of 
monitoring the efficacy of immunomodulatory therapy. 
2.3 Urinary biomarkers for melanoma diagnosis 
Urinary biomarkers for melanoma diagnosis have received much greater interest because of 
the relative ease of sample collection and handling compared with the analysis of blood or 
tissue samples, but this form of sample may lack the sensitivity required for a diagnostic 
biomarker. Of the urinary biomarkers of melanoma already identified (Table 3), 5SCD and 
6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MI2C), are intermediate metabolites in 
melanin pigment formation, and have been the most extensively studied. An increase in 
urine levels of these markers has been associated with tumor progression and low survival 
rates (Kärnell et al., 1997; Bánfalvi et al., 2000; Wakamatsu et al., 2002). In healthy patients, 
the urinary levels of these markers are influenced by age (Meyerhöffer et al., 1998), sex 
(Morishima and Hanawa, 1981; Kågedal et al., 1992), skin color (Wirestrand et al., 1985) and 
season (Ito et al., 1987), but not by pregnancy (Carstam et al., 1985). Although both 5SCD 
and 6H5MI2C have been detected in the urine of melanoma patients, because of the higher 
levels of 5SCD, this marker is considered a more reliable urinary biomarker for melanoma 
than the 6H5MI2C (Kärnell et al., 1997, 2000; Wakamatsu et al., 2006). Moreover, the 90-kDa 
glycoprotein (TA-90)(Rote et al., 1980; Euhus et al., 1989), S100A7 (Brouard et al., 2002) and 
β-human chorionic gonadotropin (Carter et al., 1995) have also been identified in the urine 
of patients with melanoma (Table 3).  
Of these urinary biomarkers, 5SCD, 6H5MI2C, and S100A7 can be considered the most 
melanoma-specific of the urinary biomarkers (Kärnell et al., 1997; Bánfalvi et al., 2000; 
Brouard et al., 2002; Wakamatsu et al., 2002). 
www.intechopen.com
 Biomarkers Functions 
Proangiogenic factors 
VEGF 1) VEGF receptor (VEGFR) ligand 
FGF 1) FGF receptor (FGFR) ligand 
EGF 1) EGF receptor (EGFR) ligand 
Placental growth factor (PIGF) 1) Neuropilin-1 and -2 receptor ligand 
TNF 1) GPCR ligand 
IL-8 (CXCL8) 1) GPCR (specially, chemokine receptor CXCR1  
and 2) ligand 
Laminin-5 2) Laminin receptor  
(e.g., integrin α6β4 and α7β1) ligand 
Osteopontin 2) Integrin αvβ3 ligand 
uPA 2) uPAR ligand 
Antigens 3) 
Melanocyte lineage/Differentiation antigens 
Tyrosinase Regulator enzyme in melanin synthesis;  
Increased in metastatic prognosis 
gp100/pmel-17 Melanin synthesis-associated melanosomal  
matrix glycoprotein;  
Increased in metastatic prognosis  
S100 proteins (e.g., S100B) Cell division and differentiation-associated  
acidic calcium-binding protein;  
Increased in metastatic prognosis 
MIA A small soluble protein; Increased in metastatic 
prognosis 
L-dopa/L-tyrosine ratio An index of tyrosinase functional activity; 
Increased in metastatic prognosis 
Melanoma-associated antigens 
TA-90 Potential immunostimulator or antineoplastic 
activator; Increased in metastatic prognosis 
Survivin (one of apoptosis inhibitors gene 
family) 
Apoptosis inhibition; Increased in metastatic 
prognosis 
Cytoplasmic/high-molecular-weight  
melanoma-associated antigen (CYT-
MAA/HMW-MAA) 
Unknown exactly, but may relate to  melanoma 
progression 
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 Biomarkers Functions 
Other antigens 
Galectin-3 A β-galactoside-binding protein;  
Increased in metastatic prognosis 
Synovial sarcoma X breakpoint-2 (SSX-2) A family of highly homologous synovial  
sarcoma X (SSX) breakpoint proteins and 
repressive gene regulator 
Gangliosides (GM2, GD2, GM3, and GD3) Group of glycosphingolipids;  
Relate to interactions between melanoma cells  
Cytokines and cytokine receptors 4) 
IL-1 Survival or proliferation-associated factor 
IL-4 Survival or proliferation-associated factor 
IL-6 Survival or proliferation-associated factor 
IL-10 Survival or proliferation-associated factor 
IL-12 Survival or proliferation-associated factor 
Soluble IL-2 receptor Survival or proliferation-associated factor Boyan
Other serologic biomarkers 
YKL-40 Unknown exactly, but may function  
as a survival or proliferation-associated factor 
C reactive protein (CRP) Unknown exactly, but may relate to tumor-
associated inflammatory response 
Lactate dehydrogenase (LDH) An indicator for liver metastasis; a  
prognostic indicator in metastatic melanoma 
 Glypican-3 (GPC3) Unknown exactly, but may function as a  
survival or proliferation-associated factor 
PKCα A survival or proliferation-associated protein 
5SCD A precursor of melanin;  
Increased in metastatic prognosis 
6H5MI2C A precursor of melanin;  
Increased in metastatic prognosis 
Serum amyloid A (SAA) A superfamily of acute-phase proteins and 
proinflammatory adipokine 
Cystatin C A potent inhibitor of cysteine proteases;  
Increased primary and metastatic melanoma 
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Biomarkers References 
5SCD Yamada et al., 1992; Kärnell et al., 1997;  
Bánfalvi et al., 2000; Wakamatsu et al., 2002 
6H5MI2C Yamada et al., 1992; Kärnell et al., 1997 
TA-90 Rote et al., 1980; Euhus et al., 1989 
S100A7 Brouard et al., 2002 
β-human chorionic gonadotropin Carter et al., 1995 
Table 3. Urinal biomarker for the diagnosis of melanoma 
2.4 Biomarkers for early melanoma diagnosis  
The early diagnosis of melanoma is closely related to an increase in survival rate. Although 
many prognostic biomarkers (mainly metastatic prognosis biomarkers) of melanoma have 
been reported, there are very few capable of allowing an early diagnosis. Glypican-3 (GPC3) 
is a membrane-bound heparin sulfate proteoglycan which is overexpressed in several 
tumors. It has been suggested that GPC3 may be a useful early stage biomarker for patients 
with the early stages of the disease (0 - II) (Nakatsura et al., 2004; Ikuta et al., 2005). 
Moreover, cyclooxygenase-2 (COX-2) (Chwirot and Kuźbicki, 2007), serum amyloid A 
(SAA) (Mian et al., 2005; Findeisen et al., 2009) and DNA methylation profiling (Conway et 
al., 2011) can be used to distinguish between early melanomas and benign nevi.  
3. Screening techniques of melanoma biomarkers 
Before the development of high throughput proteomics techniques, biomarker candidates 
were identified based on known melanoma molecular pathways and validated by 
traditional techniques such as western blotting, ELISA and immunohistochemical analysis. 
However, the recent development of proteomics has enabled novel biomarkers to be 
screened from across a much larger section of the proteome. The most widely used 
technique for this form of screening is one whereby the samples are first separated by 2-DE 
and then each protein is identified by mass spectrometry (MS). Recently, simple gel-free 
techniques such as shotgun proteomics (Liu et al., 2002) and surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS)(Petricoin et al., 
2002) have been developed. These techniques employ simple separation procedures such as 
capillary chromatography and surface chromatography prior MS analysis.  
3.1 Screening for tumor tissues and cell lines 
Biomarkers discovered from tissue samples and cultured cell lines also have utility for the 
development of diagnostic and prognostic assays. Tissue microarray is a high throughput 
technique in which many tissue samples can be screened simultaneously. This technique is 
suitable for the validation of candidate biomarkers, which are first obtained by other 
proteomics techniques. Several biomarkers of melanoma such as HSP 90 (McCarthy et al., 
2008), ING3 (Wang et al., 2007), and the epidermal growth factor receptor family member 
HER3 (Reschke et al., 2008) were validated using this technique. 
For comprehensive screening of biomarkers from lysates collected from tumor tissue and 
cultured cells, 2-DE combining MS is used as a standard method. The representative 
attempts of biomarker screening of melanoma lysates are summarized in Table 4. Since 
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tumor tissue is heterogeneous mixture of several cell types, cultured cell lines may be 
preferable for the screening of biomarkers. To search for biomarkers useful for the diagnosis 
of metastases, primary and metastatic cell lines were compared and several candidate 
biomarkers were successfully discovered (Table 4) (Bernard et al., 2003; Zuidervaart et al., 
2006; Al-Ghoul et al., 2008). Proteomics analysis of melanoma-associated fibroblast stromal 
cells revealed the aberrant expression of several proteins not detected in normal fibroblasts 
(Paulitschke et al., 2009). These proteins may promote tumor progression. However, the 
passages number of the melanoma cell lines tested was found to produce changes in the 
proteome, which may underscore the invasive character observed in melanoma cells line 
that have been passaged many times (Pardo et al., 2006).  
 
Screening methods Samples Biomarkers Remarks References 
2-DE/MALDI-TOF-MS Primary and 
metastatic melanoma 
cell lines, and normal 
melanocyte lines 
Hepatoma-derived 
growth factor (HDGF) 
Nucleophosmin B23 
Increased in 
melanoma 
Bernard 
et al., 2003 
2-DE/LC-MS/MS Uveal malignant 
melanoma (UM)  
cell lines with  
varying passages  
MUC18 
HMG-1 
Increased in 
higher 
passages 
Pardo  
et al., 2006 
2-DE/MALDI-TOF/ 
TOF-MS 
UM primary and 
metastatic cell lines 
HSP 27 
Galectin-1 
Increased in 
metastases 
Zuidervaart 
et al., 2006 
2-DE/MS/MS Primary and 
metastatic melanoma 
cell lines 
Cyclophilin A Increased in 
metastatic 
melanoma 
Al-Ghoul  
et al., 2008 
LC-MS/MS Melanoma-associated 
fibroblasts and  
normal fibroblast 
Periostin  
(a 90-kDa glycoprotein)
Stanniocalcin-1  
(a 56-kDa glycoprotein)
Increased; 
melanoma-
associated 
antigens 
Paulitschke 
et al., 2009 
2-DE/MS/MS UM with monosomy 3 
and disomy 3 
HSP 27 
Vimentin 
Increased in 
disomy UM 
Coupland  
et al., 2010 
Table 4. Biomarker screening for tumor tissues and cell lines 
3.2 Screening biomarkers obtained from serum and secreted from cultured cell lines 
Because serum samples are far less invasive to obtain than biopsied material, the discovery 
of serological biomarkers has received a great deal of attention. Well-defined biomarkers 
enable early detection, allow the appropriate classification of tumor types (which provides 
the clinician insight into the best choice of therapy), and enable the patient to be more 
thoroughly monitored for progression and regression. However, there are several 
difficulties with screening serological biomarkers: (1) the presence of abundant blood 
proteins, which may inhibit the detection of biomarkers, and (2) the low serum 
concentration of the biomarker after it is secreted from tumor tissue and diluted in the 
bloodstream (Simpson et al., 2008). Hence, processes by which the abundant blood proteins 
are removed from the sample or the target proteins are concentrated are essential to address 
these problems. As a result of these difficulties inherent in serum proteomics, the secretome 
has received much attention recently.  
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Table 5 summarizes a number of different reports in which comprehensive screening of 
biomarkers from serum and the secretome occurred. By comparing the secretome between 
melanoma and normal melanocyte, several potential biomarkers were successfully 
discovered (Pardo et al., 2007; Paulitschke et al., 2009). The traditional serological 
biomarkers of melanoma such as LDH, S100B and CRP lack sensitivity as early stage 
melanoma biomarkers. To search for early stage biomarkers, Findeisen et al. extensively 
analyzed the serum proteome of about 600 melanoma patients at each stage of the disease 
(stages I - IV) by SELDI-TOF-MS technique (Mian et al., 2005; Findeisen et al., 2009). This 
analysis led to the discovery of a new biomarker, SAA, which was found to be highly 
sensitive for detecting early stage melanoma. 
 
Screening methods Samples Biomarkers Remarks References 
2D-GE/LC-MS/MS UM cell lines and normal 
melanocytes 
gp100/pmel-17 
Cathepsin D 
Mad-9  
(syntenin 1) 
Increased in 
melanoma 
Pardo  
et al., 2007 
Multiplex 
immunobaed assay 
Serum of melanoma 
patients and healthy 
individuals 
Cytokines  
(e.g. IL-1,  
IL-6, TNF-α) 
Increased in 
patients with 
longer relapse-
free survival  
(RFS) values 
Yurkovetsky  
et al., 2007 
LC-MS/MS Malanoma cell lines and 
normal melanocyte 
Glutathione 
peroxidase 
Increased in 
malanoma 
Paulitschke  
et al., 2009 
SELDI-TOF-MS Serum of melanoma 
patients with different 
stages 
SAA Increased  
in early stages 
Mian et al., 2005 
Findeisen  
et al., 2009 
Table 5. Biomarker screening for serum and secretome of cell lines 
4. Summary and overall conclusions 
Melanoma biomarkers have the capacity not only to diagnose melanoma, but also to allow 
patients to be monitored for recurrence after surgical resection and to allow the effect of 
anticancer drug treatments to be evaluated. Advanced technologies (e.g., high throughput 
technologies in genomics or proteomics) have contributed much to the hunt for melanoma 
biomarkers in tissue samples or body fluids and have typically been MS-based or array-
based technologies. 
Several immunohistochemical, serologic and urinary biomarkers have been reported to be 
very useful diagnostic and prognostic biomarkers. However, there is a paucity of data on 
melanoma-specific biomarkers, with the exception of the melanocyte lineage/differentiation 
antigens and melanoma-associated antigens, and some urinary biomarkers such as 5SCD, 
6H5MI2C and S100A7.  
Moreover, several melanoma biomarkers with prognostic capabilities, mainly for the 
detection of metastatic disease, have been applied to clinical use. However, there is s still a 
great need to identify melanoma early-stage melanoma biomarkers, as early detection of the 
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disease is key to increasing the survival rate. Of several melanoma biomarkers identified, 
GPC3, COX-2, SAA and DNA methylation profiling may hold promise for the diagnosis of 
early melanoma.  
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